Levocarb (Levodopa, Carbidopa Monohydrate)

Levodopa crosses the blood‑brain barrier and is converted to dopamine within central neurons. Carbidopa blocks the peripheral enzyme that would otherwise convert levodopa to dopamine outside the brain, allowing more levodopa to reach the central nervous system and reducing peripheral side effects.

The appropriate dose of Levocarb is individualized by the prescribing clinician based on the patient’s disease severity, response to therapy, age, and renal or hepatic function. No fixed dosing regimen is provided here; the prescriber will set the dosage and titration schedule.

The pregnancy category for Levocarb is listed as unknown. Because the safety profile has not been established, it should only be used during pregnancy or lactation if the potential benefit justifies the potential risk, and after consultation with a healthcare professional.

To request Levocarb, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levocarb provides direct dopamine replacement, whereas dopamine agonists stimulate dopamine receptors and MAO‑B inhibitors prevent dopamine breakdown. Levodopa/Carbidopa generally offers the most robust symptomatic relief, especially in later disease stages, but may be associated with motor complications such as dyskinesia that are less common with some alternatives.

Levocarb tablets should be stored at room temperature, below 25 °C, in the original container. Keep the product away from moisture, excessive heat and direct sunlight to maintain potency and stability throughout its shelf life.

Levocarb is taken orally, usually with a full glass of water. It can be taken with or without food, but high‑protein meals may interfere with absorption, so spacing the dose from protein‑rich meals is often recommended. The exact schedule is determined by the treating physician.

Serious adverse events include dyskinesia (involuntary movements), psychosis or visual hallucinations, and severe orthostatic hypotension that can lead to syncope. Patients should be monitored closely for these reactions, and any sudden changes should be reported to a healthcare provider promptly.

Levocarb should be avoided in patients with known hypersensitivity to levodopa, carbidopa, or any excipients. It is also contraindicated in individuals currently taking non‑selective MAO inhibitors. Caution is advised for patients with severe cardiovascular disease, uncontrolled psychiatric disorders, or those prone to severe hypotension.